980 related articles for article (PubMed ID: 17878149)
1. Zoledronic acid and clinical fractures and mortality after hip fracture.
Lyles KW; Colón-Emeric CS; Magaziner JS; Adachi JD; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Lavecchia C; Zhang J; Mesenbrink P; Hodgson PK; Abrams K; Orloff JJ; Horowitz Z; Eriksen EF; Boonen S;
N Engl J Med; 2007 Nov; 357(18):1799-809. PubMed ID: 17878149
[TBL] [Abstract][Full Text] [Related]
2. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.
Black DM; Delmas PD; Eastell R; Reid IR; Boonen S; Cauley JA; Cosman F; Lakatos P; Leung PC; Man Z; Mautalen C; Mesenbrink P; Hu H; Caminis J; Tong K; Rosario-Jansen T; Krasnow J; Hue TF; Sellmeyer D; Eriksen EF; Cummings SR;
N Engl J Med; 2007 May; 356(18):1809-22. PubMed ID: 17476007
[TBL] [Abstract][Full Text] [Related]
3. Association between timing of zoledronic acid infusion and hip fracture healing.
Colón-Emeric C; Nordsletten L; Olson S; Major N; Boonen S; Haentjens P; Mesenbrink P; Magaziner J; Adachi J; Lyles KW; Hyldstrup L; Bucci-Rechtweg C; Recknor C;
Osteoporos Int; 2011 Aug; 22(8):2329-36. PubMed ID: 21153021
[TBL] [Abstract][Full Text] [Related]
4. Antifracture efficacy and reduction of mortality in relation to timing of the first dose of zoledronic acid after hip fracture.
Eriksen EF; Lyles KW; Colón-Emeric CS; Pieper CF; Magaziner JS; Adachi JD; Hyldstrup L; Recknor C; Nordsletten L; Lavecchia C; Hu H; Boonen S; Mesenbrink P
J Bone Miner Res; 2009 Jul; 24(7):1308-13. PubMed ID: 19257818
[TBL] [Abstract][Full Text] [Related]
5. [Fracture prevention in postmenopausal women with osteoporosis by an annual infusion of zoledronic acid].
Geusens PP; Lems WF
Ned Tijdschr Geneeskd; 2007 Jun; 151(26):1445-8. PubMed ID: 17633971
[TBL] [Abstract][Full Text] [Related]
6. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study.
Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL
Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older.
Boonen S; Black DM; Colón-Emeric CS; Eastell R; Magaziner JS; Eriksen EF; Mesenbrink P; Haentjens P; Lyles KW
J Am Geriatr Soc; 2010 Feb; 58(2):292-9. PubMed ID: 20070415
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid results in better health-related quality of life following hip fracture: the HORIZON-Recurrent Fracture Trial.
Adachi JD; Lyles KW; Colón-Emeric CS; Boonen S; Pieper CF; Mautalen C; Hyldstrup L; Recknor C; Nordsletten L; Moore KA; Bucci-Rechtweg C; Su G; Eriksen EF; Magaziner JS
Osteoporos Int; 2011 Sep; 22(9):2539-49. PubMed ID: 21249332
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of once-yearly zoledronic acid in Japanese patients with primary osteoporosis: two-year results from a randomized placebo-controlled double-blind study (ZOledroNate treatment in Efficacy to osteoporosis; ZONE study).
Nakamura T; Fukunaga M; Nakano T; Kishimoto H; Ito M; Hagino H; Sone T; Taguchi A; Tanaka S; Ohashi M; Ota Y; Shiraki M
Osteoporos Int; 2017 Jan; 28(1):389-398. PubMed ID: 27631091
[TBL] [Abstract][Full Text] [Related]
10. Fracture risk and zoledronic acid therapy in men with osteoporosis.
Boonen S; Reginster JY; Kaufman JM; Lippuner K; Zanchetta J; Langdahl B; Rizzoli R; Lipschitz S; Dimai HP; Witvrouw R; Eriksen E; Brixen K; Russo L; Claessens F; Papanastasiou P; Antunez O; Su G; Bucci-Rechtweg C; Hruska J; Incera E; Vanderschueren D; Orwoll E
N Engl J Med; 2012 Nov; 367(18):1714-23. PubMed ID: 23113482
[TBL] [Abstract][Full Text] [Related]
11. Reduction in the risk of clinical fractures after a single dose of zoledronic Acid 5 milligrams.
Reid IR; Black DM; Eastell R; Bucci-Rechtweg C; Su G; Hue TF; Mesenbrink P; Lyles KW; Boonen S;
J Clin Endocrinol Metab; 2013 Feb; 98(2):557-63. PubMed ID: 23293335
[TBL] [Abstract][Full Text] [Related]
12. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial.
Reid DM; Devogelaer JP; Saag K; Roux C; Lau CS; Reginster JY; Papanastasiou P; Ferreira A; Hartl F; Fashola T; Mesenbrink P; Sambrook PN;
Lancet; 2009 Apr; 373(9671):1253-63. PubMed ID: 19362675
[TBL] [Abstract][Full Text] [Related]
13. Zoledronic acid: a review of its use in the treatment of osteoporosis.
Deeks ED; Perry CM
Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264
[TBL] [Abstract][Full Text] [Related]
14. The HORIZON Recurrent Fracture Trial: design of a clinical trial in the prevention of subsequent fractures after low trauma hip fracture repair.
Colón-Emeric CS; Caminis J; Suh TT; Pieper CF; Janning C; Magaziner J; Adachi J; Rosario-Jansen T; Mesenbrink P; Horowitz ZD; Lyles KW;
Curr Med Res Opin; 2004 Jun; 20(6):903-10. PubMed ID: 15200749
[TBL] [Abstract][Full Text] [Related]
15. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT).
Jacques RM; Boonen S; Cosman F; Reid IR; Bauer DC; Black DM; Eastell R
J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515
[TBL] [Abstract][Full Text] [Related]
16. [Evidences of safety and tolerability of the zoledronic acid 5 mg yearly in the post-menopausal osteoporosis: the HORIZON project].
Dalle Carbonare L; Bertoldo F; Lo Cascio V
Reumatismo; 2009; 61(1):54-64. PubMed ID: 19370189
[TBL] [Abstract][Full Text] [Related]
17. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice.
Sieber P; Lardelli P; Kraenzlin CA; Kraenzlin ME; Meier C
Clin Drug Investig; 2013 Feb; 33(2):117-22. PubMed ID: 23184667
[TBL] [Abstract][Full Text] [Related]
18. Potential mediators of the mortality reduction with zoledronic acid after hip fracture.
Colón-Emeric CS; Mesenbrink P; Lyles KW; Pieper CF; Boonen S; Delmas P; Eriksen EF; Magaziner J
J Bone Miner Res; 2010 Jan; 25(1):91-7. PubMed ID: 19580467
[TBL] [Abstract][Full Text] [Related]
19. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis.
Hwang JS; Chin LS; Chen JF; Yang TS; Chen PQ; Tsai KS; Leung PC
J Bone Miner Metab; 2011 May; 29(3):328-33. PubMed ID: 20922438
[TBL] [Abstract][Full Text] [Related]
20. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study.
McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS;
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
